Tag Archives: Approves

FDA Approves Skyrizi (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis

FDA Approves Skyrizi (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis Print this page NORTH CHICAGO, Ill., April 23, 2019 /PRNewswire/ — AbbVie today announced that the U.S. Food and Drug Administration (FDA) approved Skyrizi (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor, for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic… Read More »

FDA Approves Expanded Monotherapy Label for Merck’s Keytruda (pembrolizumab) for First-Line Treatment of NSCLC

Print this page KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded label for Keytruda, Merck’s anti-PD-1 therapy, as monotherapy for the first-line treatment of patients with stage III non-small cell lung cancer (NSCLC) who are not… Read More »

FDA Approves Mavenclad (cladribine) Tablets for Multiple Sclerosis

FDA Approves Mavenclad (cladribine) Tablets for Multiple Sclerosis Print this page March 29, 2019 — The U.S. Food and Drug Administration today approved Mavenclad (cladribine) tablets to treat relapsing forms of multiple sclerosis (MS) in adults, to include relapsing-remitting disease and active secondary progressive disease. Mavenclad is not recommended for MS patients with clinically isolated… Read More »